Fda | featured news

FDA decides not to ban BPA in food packaging

BPA

The U.S. Food and Drug Administration announced Friday that it would not ban the use of bisphenol A, also known as BPA, in food packaging but said it would continue research on the health effects of the widely used chemical.

 

F.D.A. Is Ordered to Restrict Use of Antibiotics in Livestock

Livestock

Environmental and health groups had sued to limit the widespread use of penicillin and tetracycline to promote animal growth, which is thought to pose risks to human health.

 

Pink Slime Not Getting to the Crux of Matter

The recent outcry over ‘pink slime’, the ground beef treated with ammonium hydroxide, which has been provided to schools since the early 80s by such companies as Beef Products, Inc, has prompted the USDA to offer untreated, fattier ground beef. Beef is treated with ammonia to destroy E. Coli, but the thought of food being treated with ammonia just didn’t sit right with some people although the FDA claims that such processing of beef is safe for human consumption.

 

FDA limits 1 class of antibiotics in livestock as public health groups urge gov’t to do more

Livestock

The Food and Drug Administration says it will limit the presence of one type of antibiotics in meat, saying they could increase human resistance to the drugs. The agency said Wednesday it will restrict the use of cephalosporin antibiotics, which are often given to cattle, swine, chickens and turkeys before slaughter. The drugs are used to treat pneumonia, skin infections and other diseases in humans.

 

HHS overrules FDA, blocks over-the-counter Plan B for younger teens

Plan B Emergency Contraceptive

The emergency contraceptive Plan B will not be made available over-the-counter to younger teens, the Food and Drug Administration announced today, exposing a rift between the agency and the U.S. Department of Health and Human Services.

 

FDA Did the Right Thing in Pulling Avastin for Breast Cancer

FDA Did the Right Thing in Pulling Avastin for Breast Cancer

If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren't as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see the FDA handle more cases like this one, not less.

 

FDA questions studies of breast implant safety

FDA questions studies of breast implant safety

A U.S. Food and Drug Administration advisory panel began a two-day meeting Tuesday on silicone breast implants to consider ways to improve the effectiveness of post-approval safety studies.

 

FDA questions safety of experimental diabetes drug

Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers ...

 

FDA to hear appeal on breast cancer drug Avastin

The best-selling cancer drug in the world comes under federal scrutiny as drugmaker Roche makes a last-ditch effort to keep Avastin approved ...

 

FDA says decision to put silicone breast implants back on market was the right one

FDA says decision to put silicone breast implants back on market was the right one

The FDA was criticized in 2006 for approving the controversial implants after they'd been off the market for 14 years. But the organization says research in the last five years has shown the implants have 'reasonable assurance of safety and effectiveness.'

Senh: Isn't there a conflict of interest here? The study was conducted by the manufacturers of the implants.

 

Subscribe to this RSS topic: Syndicate content